Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple- Ascending Doses of BGB-16673 in Patients With Chronic Spontaneous Urticaria and in Healthy Participants

NCT07005713 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT07005713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07005713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple- Ascending Doses of BGB-16673 in Patients With Chronic Spontaneous Urticaria and in Healthy Participants
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Recruiting
Start date
July 19, 2025
Completion date
November 30, 2026
Enrollment
58 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria